Clearside Biomedical (NSDQ:CLSD) said today that it landed a deal with EyeKor Inc. to support its clinical trials. The companies did not disclose any financial details of the agreement.
Clearside is conducting a Phase III trial of suprachoroidally administered CLS-TA, its suspension formulation of triamcinolone acetonide, in patients with macular edema associated with non-infectious uveitis. The company is also evaluating its suprachoroidal CLS-TA, in combination with intravitreally administered Eyelea (aflibercept), in patients with macular edema associated with retinal vein occlusion.
Get the full story at our sister site, Drug Delivery Business News.
The post Clearside inks clinical development deal with EyeKor appeared first on MassDevice.
from MassDevice http://ift.tt/2nriCtu
Cap comentari:
Publica un comentari a l'entrada